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Abstract
Cyclin-dependant kinases play a central role in coordinating cell growth and division, and in sustaining proliferation of
cancer cells, thereby constituting attractive pharmacological targets. However, there are no direct means of assessing their
relative abundance in living cells, current approaches being limited to antigenic and proteomic analysis of fixed cells. In
order to probe the relative abundance of these kinases directly in living cells, we have developed a fluorescent peptide
biosensor with biligand affinity for CDKs and cyclins in vitro, that retains endogenous CDK/cyclin complexes from cell
extracts, and that bears an environmentally-sensitive probe, whose fluorescence increases in a sensitive fashion upon
recognition of its targets. CDKSENS was introduced into living cells, through complexation with the cell-penetrating carrier
CADY2 and applied to assess the relative abundance of CDK/Cyclins through fluorescence imaging and ratiometric
quantification. This peptide biosensor technology affords direct and sensitive readout of CDK/cyclin complex levels, and
reports on differences in complex formation when tampering with a single CDK or cyclin. CDKSENS further allows for
detection of differences between different healthy and cancer cell lines, thereby enabling to distinguish cells that express
high levels of these heterodimeric kinases, from cells that present decreased or defective assemblies. This fluorescent
biosensor technology provides information on the overall status of CDK/Cyclin complexes which cannot be obtained
through antigenic detection of individual subunits, in a non-invasive fashion which does not require cell fixation or
extraction procedures. As such it provides promising perspectives for monitoring the response to therapeutics that affect
CDK/Cyclin abundance, for cell-based drug discovery strategies and fluorescence-based cancer diagnostics.
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Introduction
Cell cycle progression is driven by a family of Cyclin-Dependent
Kinases (CDKs), serine/threonine protein kinases whose sequen-
tial activities promote phosphorylation of key substrates involved
in cell growth and division [1–4]. CDK/cyclin complexes are
formed through association of a catalytic CDK with a regulatory
cyclin partner, which plays a major role in promoting activation of
the CDK by inducing significant conformational changes, in
defining substrate specificity, and in targeting the heterodimeric
complex to well-defined subcellular locations [5–8]. Formation of
functional CDK/cyclin complexes is conditioned by expression of
either counterpart, although the lack of expression of one CDK or
cyclin may be compensated through formation of complexes
which do not normally occur, as has been reported in knockout
mice lacking CDK4, CDK6 or CDK2,CDK4,CDK6, so as to
ensure essential proliferative functions [9,10].
CDK/cyclin levels and activities are frequently altered in
human cancers, thereby contributing to sustain aberrant
proliferation in cancer cells [11,12]. A subset of mutations of
CDK4 and CDK6 are known to confer a selective growth
advantage through loss of natural inhibitor (CKI) binding, whilst
other mutations have been reported to promote CDK1, CDK2
or CDK4 overexpression [13,14]. In addition gene amplification,
protein overexpression, mislocalization or expression of truncated
variants of cyclins which are associated with aberrant CDK
activity have been reported in a wide range of cancers including
breast, ovarian, prostate, colorectal and lung cancer, lymphoma,
myeloma and sarcoma [15–19]. Despite the oncological rele-
vance, prognostic value and pharmacological attractivity of
CDK/Cyclins, there are no direct means of assessing their
relative abundance in living cells. Indeed, the development of
non-invasive sensing technologies to probe these biomarkers is
largely limited by their intracellular localization. As such
detection of CDKs and Cyclins remains essentially limited to
classical antigenic approaches following cell or tissue fixation
procedures, or to identification of circulating autoantibodies
reporting on them as tumour-associated antigens from sera of
cancer patients [20];yet the information obtained remains limited
to individual subunits, as are no tools that report on the status of
the biologically relevant CDK/Cyclin complexes. This not only
restricts fundamental studies of physiological or pathological
signals that modulate expression and assembly of CDK/Cyclin
complexes in living cells, it also refrains development of
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programmes by monitoring response to anticancer drugs.
In this article we report on the design and characterization of a
fluorescent peptide biosensor, whose fluorescence increases in a
sensitive fashion upon recognition of CDK/Cyclins, and which
retains endogenous CDK/Cyclin complexes from cell extracts.
CDKSENS biosensor was further applied to assess the relative
abundance of these kinases in living cells, through fluorescence
imaging and ratiometric quantification, following facilitated
delivery by a non-covalent cell-penetrating peptide. We show that
this fluorescent peptide biosensor/carrier strategy allows to detect
subtle differences in CDK/Cyclin levels between different cell
lines, or when tampering with the levels of a single CDK or cyclin,
in a standardized and sensitive, yet non-invasive fashion.
CDKSENS is the first biosensor to afford direct readout of
CDK/Cyclin levels in living cells, providing a unique opportunity
to identify cells in which these complexes are overexpressed, or on
the contrary present defective assemblies, thereby offering
promising perspectives for cancer diagnostics, for monitoring
response to therapeutics, and for cell-based drug discovery
strategies.
Results
Design and in vitro characterization of a CDK/Cyclin
peptide biosensor
In order to develop a means of probing CDK/cyclin complexes
both in vitro and in living cells, we resolved to design a fluorescent
biosensor that would report on the relative levels of these
complexes with high selectivity and sensitivity. To this aim, we
designed a 29mer peptide biosensor, CDKSENS, to recognize
molecular interfaces specific to CDK-cyclin complexes, which
could be labelled with a synthetic fluorescent probe whose spectral
properties would be affected upon docking of the biosensor onto
CDK/cyclin complexes. Since canonical substrate sequences
alone are fairly unspecific for cyclin-dependent kinases,
CDKSENS was deliberately designed as a biligand, one moiety
intended to bind the CDK, the other the cyclin. Most CDK-cyclin
substrates show strong dependency on the cooperative recognition
of a consensus S/TP phosphorylation site by the CDK and a distal
RXL cyclin-binding motif that is recruited by a shallow,
hydrophobic patch known as the cyclin groove, which enhances
overall substrate affinity and catalytic efficiency [21–23].
CDKSENS was therefore designed to bear a CDK-binding
moiety derived from the CDC6 substrate of CDK2 [23] in which
the phophorylatable serine residue was substituted by a glycine to
avoid phosphotransfer from the CDK, HHAGPRK, and a cyclin-
binding moiety bearing the RXL recruitment sequence derived
from the retinoblastoma pocket protein p107, RRLFGE [24].
Since the RXL substrate recognition site in the cyclin is 40 A ˚ from
the catalytic site of the CDK, they were joined by a 15mer linker
derived from the natural sequence of p107, immediately upstream
of the cyclin-binding motif; the first serine within this sequence was
replaced by a cysteine, thereby providing an unique accessible
thiol for coupling of a fluorescent probe at a central position
between the CDK- and the Cyclin-binding motifs RVHER-
YCSPTAGSAK. A schematic representation of CDKSENS is
shown in Fig. 1A, together with the 3D models of CDK2/
cyclinA/substrate peptide and CDK2/cyclinA/p107 peptide.
In order to establish the validity of this design, we first asked
whether CDKSENS could interact with its targets in vitro. To this
aim, it was labelled on its internal cysteine with FITC, and titrated
with purified, recombinant forms of CDKs and cyclins. Binding of
CDK and Cyclin partners resulted in significant enhancement in
CDKSENS fluorescence with a 3–4 fold increase (300–400%) at
saturation (Fig. 1B). When CDKSENS docks onto CDK/cyclin
complexes, the fluorescent probe is introduced into an entirely
different environment from its free form in solution, and is
therefore subject to changes in solvent polarity which directly
affect its spectral properties, a process known as solvatochromism
[25]. FITC is particularly sensitive to changes in its environment,
and this is also the case for cyanine probes such as Cy3 and Cy5
(Fig. S1A), but not for Alexa probes, which when coupled to
CDKSENS did not yield any significant fluorescence enhance-
ment upon titration with CDK/Cyclins (data not shown). Hence
the choice of an environmentally-sensitive fluorescent probe is
essential for CDKSENS to report on the presence of CDK/Cyclin
complexes. Dissociation constants determined from the titration
curves revealed that CDKSENS exhibits high affinity for both
CDKs and cyclins, in the 100–200 nM and 60–70 nM range,
respectively, with the exception of cyclin B, whose affinity was 7–8-
fold lower than other cyclins, consistent with the presence of two
mutations close to its cyclin-recruitment patch (Glu220 to Gln211
and Tyr280 to Phe271) previously reported to reduce affinity for
RXL substrates [26] (Table 1). We further found that
CDKSENS biosensor presents significantly higher affinity for the
CDK2-cyclinA complex than for monomeric CDK2 or cyclin A,
with a dissociation constant value of 8 nM+/25 nM. CDKSENS
presented an equally high affinity for CDK1-cyclinB, CDK2-
cyclinB and CDK1-cyclin A complexes, with dissociation constant
values of 6+/22 nM, 9+/24 nM, 18+/26 nM respectively
(Table 1 and Fig. S1B). Taken together, these data indicate
that the choice of the fairly conserved CDK- and Cyclin-binding
sequences allows CDKSENS to bind all CDKs and cyclins, and
clearly demonstrate that its biligand structure ensures preferential
recognition of CDK/cyclin complexes over monomeric CDKs
and cyclins. In contrast, titration with GST or MBP did not affect
the fluorescence of CDKSENS-FITC, inferring there was no
unspecific binding. Likewise, FITC-labelled control peptides
derived from the substrate sequence alone, or from an irrelevant
control peptide, lacking both the consensus substrate sequence and
the RXL motif (Ctrl peptide: VESSDTIDNVKSKIQDKEGC)
did not recognize recombinant CDKs or cyclins. Finally, having
assessed the sensitivity and affinity of CDKSENS for its targets, we
examined the kinetics of CDKSENS response to a fixed
concentration of target. This experiment revealed that CDKSENS
responds fairly rapidly to CDK2/CyclinA, the first signs of
fluorescence enhancement appearing after a lag of 350 s (6 min)
and reaching complete enhancement after 600 s (10 min)
(Fig. 1C).
CDKSENS binds endogenous CDK/Cyclin complexes from
cell extracts
To further evaluate the ability of CDKSENS to recognize
endogenous CDK/cyclin complexes from cell extracts, we
performed pulldown experiments following immobilization of
CDKSENS on CNBr Sepharose. These experiments revealed that
in HeLa cells, in which all CDKs and Cyclins are well expressed,
all are equally well retained by CDKSENS, but not by the Ctrl
peptide which lacks all relevant CDK and Cyclin binding
sequences (Fig. 2A). Likewise, pulldown experiments performed
with the osteosarcoma cell line U20S showed that CDKSENS
efficiently retained all CDKs and cyclins (Fig. 2B and C).
However pulldowns performed with cell lines in which cyclins
were not expressed at wild-type levels, or as full-length proteins,
such as lung cancer A549 and breast cancer MCF-7 cells, revealed
that the corresponding CDK partner was not retained by
CDKSENS (Fig. 2B and C). For instance CDKSENS retained
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but not from MCF7 or A549 cells, which both lack wildtype levels
of cyclin A and B. CDK4 complexes were retained by CDKSENS
from HeLa, U20S and MCF7 cells, but not from A549 cells, which
do not express detectable levels of D cyclins. These data indicate
that CDKSENS does not recognize monomeric CDKs in cell
extracts, but requires the presence of cyclins to recognize stable
CDK/cyclin complexes, in agreement with the preferential affinity
of CDKSENS for recombinant CDK/Cyclin complexes over
monomeric subunits reported in Fig. 1 and Table 1.
Cellular Internalization and characterization of the CDK/
Cyclin peptide biosensor
In order to apply CDKSENS to live-cell imaging, it was labelled
with cyanine probe Cy3, which was equally sensitive in reporting
on the presence of CDK/Cyclins in vitro (Fig. S1A). CDKSENS-
Figure 1. Design and in vitro characterization of CDKSENS. A. Sequence and schematic representation of CDKSENS together with the crystal
structures of CDK2/cyclin A/HHASPRK peptide substrate (PDB 1QMZ) and CDK2/cyclin A/p107 RRLFGE peptide (PDB 1H28). CDK2 is shown in green,
the PSTAIRE helix in red, and the peptide substrate in magenta; cyclin A is in cyan with the alpha 5 helix in yellow and the p107 peptide in orange
B.Titration of 200 nM CDKSENS-FITC and Ctrl-FITC peptide with recombinant CDKs, cyclins, preformed CDK/cyclin complexes, GST or MBP. Changes
in fluorescence are shown relative to the initial fluorescence of CDKSENS (or Ctrl) in the absence of target C. Kinetics of 200 nM CDKSENS response to
a fixed concentration of CDK2/Cyclin A. Changes in fluorescence over time are relative to CDKSENS fluorescence in the absence of CDK2/Cyclin A.
doi:10.1371/journal.pone.0026555.g001
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which we have previously shown to efficiently deliver fluores-
cently-labelled peptides into cultured cells [27] (Fig. 3A).
CADY2/CDKSENS-Cy3 complexes overlaid onto HeLa cells
efficiently promoted cellular uptake of the fluorescent biosensor
(Fig. 3B). Phase contrast and fluorescence time-lapse microscopy
were employed to monitor changes in the distribution of
CDKSENS-Cy3 fluorescence, together with changes in cell
morphology through the cell cycle, revealing the dynamic
distribution of the biosensor in the cytoplasm through interphase,
gradually accumulating around the nucleus prior to mitosis
(Fig. 3C and Movie S1). In order to determine whether the
subcellular localization of CDKSENS overlapped with that of its
cellular targets, HeLa cells into which CDKSENS-Cy3 had been
introduced were fixed and indirect immunofluorescence was
performed with antibodies directed against CDK1, CDK2, Cyclin
A, Cyclin B or Cyclin E (Fig. 3D and Fig. S2). Comparison
between the subcellular localization of CDKSENS-Cy3 and that
of the different CDKs and cyclins by confocal microscopy did not
reveal significant lack of colocalization of the fluorescent biosensor
with any CDK or cyclin, in line with the ability of CDKSENS to
recognize a broad range of CDK/cyclin complexes, whose
differential patterns of expression, assembly and localization
overlap throughout the different phases of the cell cycle.
CDKSENS reports on the relative abundance of CDK/
Cyclins in living cells
In order to apply CDKSENS to the quantification of
endogenous CDK/Cyclins in living cells, independently of cell
morphology, we devised a strategy based on the ratiometric
quantification of CDKSENS-Cy3 fluorescence with respect to that
of the Ctrl peptide labelled with Cy5, which was equally well
internalized into HeLa cells with CADY2 (Fig. S3). Fluorescently-
labelled CDKSENS and Ctrl peptide were complexed to CADY2
and introduced into living cells, and the fluorescent signal of these
different species was measured directly by live-cell imaging. The
ratio of CDKSENS-Cy3/Ctrl-Cy5 fluorescence was then deter-
mined on 3–4 fields of 10–15 cells and the average value was used
to reflect the relative abundance of CDK/Cyclin.
We first verified whether differential expression of a single CDK
or cyclin was sufficient to measure quantitative differences through
this approach. To this aim, we co-delivered fluorescently-labelled
CDKSENS and Ctrl peptide into the HT2-19 cell line, in which
CDK1 expression is under control of an IPTG-inducible promoter
[28]. When these cells were grown in the absence of IPTG for 4
Table 1. Dissociation constant values and fluorescence
enhancement of CDKSENS-FITC upon titration with
recombinant CDKs, cyclins or preformed CDK/cyclin
complexes.
Recombinant Target Kd (nM) Fluorescence enhancement (fold)
GST-CDK1 114+/242 4.4
GST-CDK2 193+/233 4
GST-Cyclin A 71+/218 2.1
MBP-Cyclin B1 467+/2256 3
GST-Cyclin E 58+/223 2.4
GST-CDK2/Cyclin A 8+/253 . 1
GST-CDK1/Cyclin B 6+/222 . 5
GST-CDK2/Cyclin B 9+/242 . 5
GST-CDK1/Cyclin A 18+/262 . 4
GST no binding no variation
MBP no binding no variation
Ctrl/GST-CDK2 no binding no variation
Ctrl/GST-Cyclin A no binding no variation
doi:10.1371/journal.pone.0026555.t001
Figure 2. CDKSENS binds CDK/Cyclin complexes from cell extracts. A, Pulldown experiments performed with immobilized CDKSENS or Ctrl
peptide (Ctrl) and from HeLa cell extracts reveal that all CDKs and Cyclins are retained specifically by CDKSENS, not by Ctrl peptide. B,Western blots of
CDKs and Cyclins in normalized total extracts from HeLa, U20S, MCF-7 and A549 cells, as indicated C, Pulldown experiments performed as described
in (A) with the cell lines described in (B); CDKSENS (SENS) Ctrl peptide (control); Western blotting for CDK1, CDK2 and CDK4.
doi:10.1371/journal.pone.0026555.g002
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significantly reduced (.80%) and consistently, CDKSENS-Cy3/
Ctrl-Cy5 ratio was 20% lower in these cells, compared to cells
grown with 50 uM IPTG (Fig. 4A, Table 2, Table S1).
In a second set of experiments, HeLa cells were treated siRNA
targeting CDK2, leading to a partial reduction of CDK2 protein
levels (50%) detected by Western blotting. Ratiometric quantifi-
cation of CDKSENS-Cy3/Ctrl-Cy5, a significant decrease in the
fluorescence ratio, compared to cells treated with siRNA targeting
luciferase (Fig. 4B, Table 2), with an average difference of 20%
and a very low standard deviation between independent sets of
experiments, indicative of the robustness of this approach (Table
S1). Finally, we asked whether CDKSENS could report on
differences of a single cyclin, which would consequently affect the
assembly of CDK/Cyclin complexes. HeLa cells treated with
siRNA targeting CyclinB, yielded on average 15% lower
CDKSENS-Cy3/Ctrl-Cy5 values compared to mock-treated cells,
which could be associated with a 36% knockdown of CyclinB
protein levels probed by Western blotting (Fig. 4C, Table 2,
Table S1). Taken together, these experiments indicate that
CDKSENS is sufficiently sensitive to measure differences in the
relative abundance of CDK/cyclin complexes when tampering
with one single CDK or cyclin subunit.
CDKSENS reports differences in CDK/Cyclin levels
between healthy and cancer cells
Since many cancer cells exhibit alterations in the relative
abundance of CDKs and Cyclins, we asked whether CDKSENS
could be applied to highlight differences in CDK/Cyclin levels
between healthy and cancer cells. To this aim, we first chose to
compare healthy human foreskin HS68 fibroblasts with the HeLa
cervical cancer cell line. As shown in Fig. 5A, Western blotting of
different CDKs and Cyclins in normalized cell extracts reveals
significantly higher levels of Cyclin B, and somewhat higher levels of
Cyclin A, and CDK4 in HeLa cells than in HS68 fibroblasts.
Consistent with this, pulldown experiments revealed a net reduction
in the levels of all CDK/Cyclin complexes retained by CDKSENS
from HS68 relative to HeLa cell extracts. CDKSENS-Cy3 and Ctrl-
Cy5 were co-delivered into these cell lines and their fluorescence was
measured by live-cell imaging. Ratiometric quantification of
CDKSENS-Cy3/Ctrl-Cy5 consistently revealed greater values for
HeLa cells, with an average difference of 15% (Fig. 5B, Table 3).
Figure 3. CADY-mediated delivery and characterization of CDKSENS subcellular localization. A, Schematic representation of CDKSENS
complexation with CADY2 and delivery into cultured cells B, CDKSENS-Cy3 complexed with CADY2 at 40:1 ratio is efficiently internalized by HeLa cells
(lower panels) in contrats to CDKSENS-Cy3 alone (upper panels). C, Timelapse micrographs of dividing cells: phase contrast (upper panels) and
spectral representation of relative CDKSENS-Cy3 fluorescence intensity (bottom panels). D, Subcellular localization of CDKSENS-Cy3 delivered into
HeLa cells with CADY2, and of endogenous CDKs and Cyclins detected by indirect immunofluorescence and imaged by confocal microscopy. Bars in
(B), (C) and (D) correspond to 20 um.
doi:10.1371/journal.pone.0026555.g003
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between different cancer cell lines, whose features have already
been described above in Fig. 2, using the HeLa cell line as a
reference. CDKSENS-Cy3 and the Ctrl-Cy5 peptide were
introduced into each of these cell lines, and the relative
fluorescence of CDKSENS-Cy3 over that of Ctrl-Cy5 was
determined. As reported in Fig. 6 and Table 3, ratiometric
quantification of CDKSENS-Cy3/Ctrl-Cy5 did not reveal a
significant difference between HeLa cells and the U20S osteosar-
coma cell line, in line with the Western blot of total extracts and of
pulldown experiments presented in Fig. 2, which shows essentially
identical levels of all CDKs and Cyclins and of CDK/Cyclin
complexes in these two cell lines. In contrast, CDKSENS-Cy3/
Ctrl-Cy5 values were consistently 18–20% lower in A549 and
MCF7 cells compared to the HeLa cell line, indicative of lower
relative abundance of CDK/Cyclin complexes (Fig. 6, Table 3),
in agreement with the data shown in Fig. 2. For each of these cell
lines, ratiometric values were determined from several indepen-
dent sets of experiments, which revealed very similar relative
values for each cell type, and reproducible differences between cell
lines, indicative of the robustness of this approach (Table S1).
Discussion
Together with advances in live-cell imaging technology, the
development of fluorescent probes that report on enzyme levels,
activities or conformations has provided new perspectives for the
study of dynamic biological processes, for monitoring the cell cycle
status and cell proliferation, whilst also offering new tools for
diagnostics and drug discovery [29–32]. Whilst genetically-
encoded single-chain FRET-based activity reporters have been
successfully applied to probe a broad variety of enzymatic
activities, combined efforts in fluorescence chemistry and chemical
biology have lead to the design of an equally potent class of
biosensors that incorporate small synthetic probes with unique
spectral properties, such as enhanced photostability and environ-
Figure 4. CDKSENS reports differences that affect CDK/Cyclin abundance associated with a single CDK or cyclin in cellulo. A, HT2-19
cells cultured with (+) IPTG or without (wo) for 4 days. B, HeLa cells treated with 100 nM siRNA directed against CDK2 (sicdk2) or luciferase (siLuc). C,
HeLa cells treated with 100 nM siRNA directed against Cyclin B1 (sicycB1) or luciferase (siLuc). All left panels present Western blots of normalized cell
extracts. Right panels illustrate representative examples of CDKSENS-Cy3/Ctrl-Cy5 fluorescence between treated and untreated cells, performed on 3–
4 different fields of 10–15 cells. The mean calculated between the values of 3–4 different fields, is shown together with the standard deviation (see
Table 2).
doi:10.1371/journal.pone.0026555.g004
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Synthetic peptide and polypeptide biosensors that report on target
concentration, enzymatic activity or protein conformation in
complex biological samples, cell extracts and living cells, have been
successfully developed, as exemplified by the LifeAct biosensor of
actin dynamics [33], solvatochromic GTPase bioprobes [34],
dark-quench reporters [35], chelation-enhanced bioprobes [36],
and smart peptide probes that are selectively delivered into tumor
cells following enzymatic activation [37], to name but a few. Aside
from the latter example, one of the major drawbacks of nongenetic
biosesnors is their inability to cross cell membranes, thereby
requiring facilitated delivery into cells. Nonetheless, major
advances in the field of peptide and protein delivery over the
last twenty years have provided new strategies to circumvent this
issue, in particular the use of protein transduction domains and
cell-penetrating peptides, which constitute most efficient means of
introducing biological molecules into living cells and in vivo [38].
In this study, we have combined the design of a fluorescent
peptide biosensor, CDKSENS, that reports on the presence of
CDK/Cyclin complexes through sensitive changes in fluorescence,
with a non-invasive delivery strategy based on a cell-penetrating
peptide which requires neither chemical coupling nor genetic
fusion, thereby ensuring efficient cellular uptake and release of the
bioprobe into the intracellular milieu. The peptide nature of
CDKSENS makes it very easy to handle and straightforward to
label and allows for a controlled and direct application both in
vitro and in cellulo. Here we demonstrate that this biosensor can
be used to probe the relative abundance of CDK/cyclins in vitro,
in cell extracts, and in living cells in a standardized fashion
through ratiometric quantification of its fluorescence over that of a
control peptide.
A good biosensor should recognize and bind its target with
respectable affinity and specificity, and exhibit changes in
fluorescence which reflect the presence or activity of the target
in a sensitive fashion, both with respect to intensity and speed.
CDKSENS was designed to bear both a CDK- and a cyclin-
binding moiety, in order to ensure preferential recognition of
CDK/Cyclin complexes, which are biologically relevant, as
opposed to monomeric CDKs and cyclins, which do not display
any activity. We have shown that through its biligand design,
CDKSENS biosensor preferentially binds CDK/Cyclin complex-
es in vitro, and that it cannot bind a CDK in the absence of its
cyclin partner in cell extracts. Hence this feature ensures specific
and high affinity recognition CDK/Cyclin complexes.
We have further shown that CDKSENS can be applied to
probe the relative abundance of CDK/cyclins in living cells in a
standardized and sensitive fashion through ratiometric quantifica-
tion of its fluorescence over that of an inert control. As shown in
the experiments with the HT2-19 cell line, and with siRNA
targeting cyclin B or CDK2, CDKSENS is sufficiently sensitive to
report on differences in the levels of a single CDK or cyclin. In this
respect, it is noteworthy that a 36% decrease in the levels of cyclin
B alone was consistently associated with a 15% reduction in
CDKSENS-Cy3/Ctrl-Cy5 ratio, whilst changes in a single CDK
yielded 20% difference in this value. We have also shown that
CDKSENS distinguishes cell lines expressing high levels of CDK/
Cyclins, such as HeLa and U20S cells, from cell lines expressing
reduced levels of several complexes, such as HS68 fibroblasts, the
breast cancer cell line MCF-7 or the lung cancer cell line A549. In
contrast, when there are practically no differences between CDK
and Cyclin levels between two cell lines, as for U2OS and HeLa
cells, in which Western blotting indicates less than 5% difference
in CyclinD levels only, ratiometric quantification of CDKSENS/
Ctrl yielded essentially identical values. These data demonstrate
that differences in CDKSENS/Ctrl values are truly associated
with differences in the relative abundance of CDK/Cyclins,
underscoring the specificity and sensitivity of this technology.
CDKSENS technology offers several advantages over strategies
relying on antigenic detection. First, CDKSENS provides
information on the status of CDK/Cyclin complexes which is
not conveyed by antibodies that recognize individual subunits.
Second, CDKSENS technology is essentially non-invasive, since it
is based on live-cell fluorescence imaging and does not call for cell
fixation or extraction procedures. Third, CDKSENS allows for
rapid detection of cells that present differences in CDK/Cyclin
levels, without discriminating between one or another complex;
Table 2. Ratiometric quantification of CDKSENS-Cy3/Ctrl-Cy5 fluorescence in HT2-19 cells induced to express CDK1 (+IPTG) or not
(WO), in HeLa cells treated with siRNA targeting luciferase (siLuc), or CDK2 (siCDK2), or cyclin B (siCycB).
Fluorescence CDKSENS-Cy3/Ctrl-Cy5 Mean Ratio CDKSENS-Cy3/Ctrl-Cy5
HT219+IPTG WO IPTG Mean HT219+IPTG Mean WO IPTG
5,565739401 4,247635348 5,37+/20,18 4,36+/20,21
5,210906398 4,236269139 Relative Mean Ratiometric Values
5,344875205 4,612407668 1+/20,033 0.81+/20,04
siLuc siCDK2 Mean siLuc Mean siCDK2
7,674257647 5,655287202 7,63+/20,14 5,86+/20,50
7,428888119 6,156148923 Relative Mean Ratiometric Values
7,771713461 5,252854394 1+/20,019 0.77+/20,066
7,641928691 6,364627584
siLuc siCycB Mean siLuc Mean siCycB
6,502745388 5,837569677 6,8+/20,38 5,66+/20,19
6,673396111 5,682751484 Relative Mean Ratiometric Values
7,226137167 5,468652038 1+/20,055 0.83+/20,027
In each experiment, the ratiometric value is given for 3 or 4 fields of cells (n=10–15) and the mean ratiometric values are given together with their standard deviation.
These values were then normalized to the highest mean ratiometric value.
doi:10.1371/journal.pone.0026555.t002
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present defects in several CDKs and Cyclins.
Finally, since alterations in CDK/cyclin levels have been
reported in a wide variety of cancers, and associated with negative
prognosis, it is important to identify cells in which overexpression
of these complexes is truly relevant for therapeutic intervention.
We have shown that CDKSENS provides a unique means of
assessing the relative abundance of CDK/Cyclins in living cells, in
a standardized fashion, and a good indication as to whether cells
express high levels of these heterodimeric kinases, or decreased or
defective assemblies. These data have strong implications for
diagnostic and therapeutic applications. Indeed, we have previ-
ously shown that reduction of cyclin B1 levels by siRNA or PNA
administration efficiently blocks growth of tumour xenografts in
mice [39,40], and we show here that CDKSENS provides a
sensitive readout of differences in cyclin B1 levels following
treatment of cultured cells with cyclin B1 siRNA. Hence
CDKSENS presents strong potential for monitoring response to
therapeutic strategies targeting CDKs or cyclins, and offers
promising perspectives for development of cancer diagnostics,
and cell-based drug discovery approaches.
Materials and Methods
Peptide synthesis, protein expression, purification and
labelling
CDKSENS and Ctrl peptides were purchased from GL
Biochem, (Shanghai, China), labelled on their unique cysteine
with fluorescein-isothiocyanate (FITC), Cy3- or Cy5-maleimide,
and further purified on NAP-5 columns (GE Healthcare).
Recombinant Glutathione-S-transferase (GST)-CDKs and cyclins
were expressed in E.coli and purified by chromatography as
described previously [41].
Steady-State Fluorescence Titration Experiments
Titration experiments were performed at 25uC in a Polarstar
Spectrofluorimeter (BMG Labtech). 200 nM FITC-labelled
CDKSENS were titrated with purified, recombinant GST-tagged
CDK1, CDK2, cyclins A, and E1, MBP-cyclin B, GST or MBP in
200 ul potassium phosphate buffer, pH 7.2, 150 mM NaCl at
25uC in 96-well microplates, and changes in fluorescence emission
were recorded at 520 nm following excitation at 485 nm. Data
analysis and curve fitting were performed using the GraFit
Software (Erathicus Ltd) and a standard quadratic equation, as
described previously [41]. It should be noted that cleaving either
GST or MBP tag resulted in significant precipitation and loss of
recombinant CDKs and cyclins; therefore fusion proteins were
used in all assays.
Cell Culture, extract preparation and pulldown
experiments. Cell culture media, serum and antibiotics were
purchased from Invitrogen. HeLa, HS68, A549, MCF-7 and
U2OS cells were obtained from ATCC and were cultured in
Dulbecco’s Modified Eagle Medium (DMEM)+Glutamax
supplemented with 10% Fetal Calf Serum (FCS), 1 mM
penicillin and 1 mM streptomycin at 37uC in an atmosphere
containing 5% CO2. HT2-19 cells, provided by Dr. A.Porter,
were cultured in DMEM supplemented with non essential amino
acids, antibiotics, sodium pyruvate, glutamine, and 10% FCS and
grown with 50 uM isopropyl-thiogalactoside (IPTG) for maximal
induction of CDK1 [28]. Cell extracts were prepared in lysis
Figure 5. CDKSENS reports differences in the overall abun-
dance of CDK/cyclins between HeLa cells and HS68 fibroblasts.
A, Western blots of CDKs and Cyclins in normalized total extracts (Inp)
and pulldowns from normalized HeLa or HS68 cell extracts B,
Representative example of CDKSENS-Cy3/Ctrl-Cy5 fluorescence mea-
sured in HS68 and in HeLa cells. The mean calculated between the
values of 3 different fields of 10–15 cells, is shown together with the
standard deviation (see Table 3).
doi:10.1371/journal.pone.0026555.g005
Probing the Relative Abundance of CDK/Cyclins
PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e26555buffer containing 50 mM TrisHCl, pH 7.4, 150 mM NaCl, 0.1%
NP40, 0.1% Deoxycholate, 2 mM EDTA, 1 mM
phenylmethlsulfonyl fluoride (PMSF), CompleteTM protease
inhibitors (Roche), 50 mM NaF, 40 mM b-Glycero-phosphate,
1 mM Na3VO4 and normalized following spectrophotometric
dosage at 280 nm. For pulldown experiments, CDKSENS or Ctrl
peptide were crosslinked to CNBr Sepharose beads, then
incubated with equal concentrations of HeLa cell extracts for
1 hr. Samples were then processed for SDS-PAGE and CDK,
Cyclin retention was detected by Western blotting.
Antibodies for Western Blotting and Indirect
Immunofluorescence
Antibodies against Cyclin A (H432, sc-751), Cyclin B1 (GNS1,
sc-245), Cyclin D1 (C20, sc-717), Cdk1 (C19, sc-954) Cdk2 (M2,
sc-163), and Cdk4 (C22, sc-260) were purchased from Tebu-Bio
(Santa-Cruz), anti-actin from Sigma (A2668), and used at 1:1000
dilution for Western blotting, except for anti-cyclin B1 at 1:500
dilution, 1:100 for indirect imunofluorescence. Secondary anti-
bodies labelled with Alexa-488 were used for indirect immunoflu-
orescence.
siRNA Transfections
siRNA targeting Cyclin B was a Smart Pool
TM M003206-02
purchased from Dharmacon. SiRNA targeting CDK2: 59-AAG-
GUGGUGGCGCUUAAGAAA-39 and Luciferase: 59-CUUAC-
GCUGAGUACUUCGATT-39 were purchased from Eurogentec.
siRNA transfections were performed for 72 h with the cell-
penetrating siRNA carrier CADY as described previously [42].
Cell-penetrating peptide-mediated delivery
For cellular uptake, 3 uM CDKSENS or control peptide were
complexed with the cell-penetrating peptide CADY2 at 1:40
molar ratio in 100 ul PBS for one hour at 37uC, overlaid onto cells
for 15 min, then for 45 min in the presence of DMEM, and finally
complemented with 10% serum, as described previously [27].
Microscopy
For fixed observations, cells were treated for 20 minutes with
paraformaldehyde, nuclei were stained with Hoechst 33342
(Sigma), and cells were mounted with Prolong Gold AntiFade
Reagent (Invitrogen). Epifluorescence images were acquired on a
Leica DM6000 microscope (Leica Microsystems) piloted by the
Metamorph software (Universal Imaging). For colocalization
experiments, images were acquired on a Zeiss axioplan2/
LSM510 META confocal microscope. Live-cell imaging was
Table 3. Ratiometric quantification of CDKSENS-Cy3/Ctrl-Cy5





HeLa HS68 Mean HeLa Mean HS68
7,20930083 6,306949025 7.21+/20,28 6.14+/20,35
6,928643917 6,379195062 Relative Mean Ratiometric Values
7,497741061 5,744844153 1+/20,039 0.85+/20,048
HeLa U20S Mean HeLa Mean U20S
7,462551653 6,244561064 6,79+/20,53 7,16+/20,65
6,964679638 7,168471954 Relative Mean Ratiometric Values
6,503735882 7,702927701 1+/20,079 1,05+/20,095
6,247960678 7,517560305
HeLa MCF7 Mean HeLa Mean MCF7
6,99509956 6,313753978 7,29+/20,39 5,99+/20,33
7,723968439 5,518310547 Relative Mean Ratiometric Values
6,928643917 6,099266915 1+/20,053 0.82+/20,046
7,497741061 6,029347325
HeLa A549 Mean HeLa Mean A549
6,436566914 5,578696443 6,72+/20,37 5,44+/20,16
7,132974124 5,257761322 Relative Mean Ratiometric Values
6,589420498 5,472799273 1+/20,054 0.81+/20,024
In each experiment, the ratiometric value is given for 3 or 4 fields of cells
(n=10–15) and the mean ratiometric values are given together with their
standard deviation. These values were then normalized to the highest mean
ratiometric value.
doi:10.1371/journal.pone.0026555.t003
Figure 6. CDKSENS allows to assess the relative abundance of
CDK/cyclins in different cancer cell lines. CDKSENS-Cy3/Ctrl-Cy5
fluorescence was determined between different cancer cell lines A,
HeLa and U20S; B, HeLa and A549; C, in HeLa and MCF7. The mean
ratiometric value corresponding to CDKSENS-Cy3/Ctrl-Cy5 was calcu-
lated between the values measured in 3–4 different fields of 10–15 cells,
is shown together with the standard deviation (see Table 3).
doi:10.1371/journal.pone.0026555.g006
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software. Images were processed with ImageJ software.
Fluorescence quantification and statistical analysis
CDKSENS-Cy3 and Ctrl-Cy5 were complexed individually
with CADY2 and codelivered into cells. Live-cell imaging
acquisitions were substracted for background signal corresponding
to minimal fluorescence levels using Metamorph. Image J was then
used for image analysis. Regions of interest (ROI) corresponding
to 10–15 cells in which fluorescence appeared homogeneous were
designed and the mean grey levels of fluorescence for each channel
(Cy3 and Cy5) were quantified within these ROIs. For each
experiment, and the mean ratiometric value of CDKSENS-Cy3/
Ctrl-Cy5 was calculated from 3–4 different ROIs. Each experi-
ment was performed 3–4 times to assess the robustness of the
quantification strategy. All statistical analyses are presented by the
mean and standard deviation.
Supporting Information
Figure S1 Further in vitro characterization of
CDKSENS. (A) Titration of CDKSENS-Cy3 with recombinant
GST-CDK2 and GST-Cyclin A (B) Titration of CDKSENS-
FITC with preformed complexes of CDK2/Cyclin B (K2/B),
CDK1/Cyclin A (K1/A) and CDK1/Cyclin B (K1/B).
(TIF)
Figure S2 Colocalization of CDKSENS, CDKs and
Cyclins. Low magnification of Fig. 3D. Subcellular localization
of CDKSENS-Cy3 delivered into HeLa cells with CADY2, and of
endogenous CDKs and Cyclins detected by indirect immunoflu-
orescence and imaged by confocal microscopy.
(TIF)
Figure S3 CADY2-mediated delivery of Ctrl peptide.
Cy3-labelled Ctrl peptide complexed with CADY2 at 1:40 ratio is
efficiently internalized by HeLa cells (lower panels), in contrast to
Cy3-labelled Ctrl peptide alone (upper panels).
(TIF)
Table S1 Average ratiometric quantification of
CDKSENS-Cy3/Ctrl-Cy5 fluorescence determined from
individual sets of experiments and normalized to the
highest mean ratiometric value.
(TIF)
Movie S1 Dynamics of CDKSENS-Cy3 in HeLa cells.
(AVI)
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